menu
    • menu
    [{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Estetrol","moa":"||Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Estetrol","moa":"||Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Pharma \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mayne Pharma

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mayne Pharma

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Estetrol,Drospirenone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mayne Pharma Announces FDA Filing Acceptance of New Drug Application for E4/DRSP in the US

                            Details : New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 24, 2020

                            Lead Product(s) : Estetrol,Drospirenone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mayne Pharma

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mayne Pharma

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Estetrol,Drospirenone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mayne Pharma Submits New Drug Application for E4/DRSP to the FDA

                            Details : Mayne Pharma has submitted a New Drug Application to the US FDA, seeking marketing authorisation for E4/DRSP.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 16, 2020

                            Lead Product(s) : Estetrol,Drospirenone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth